cal and clinical development
of our products; the ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the ability to complete
and maintain corporate alliances relating to the development and
commercialization of our technology and products; market acceptance of our
technology and products; the competitive environment and impact of
technological change; and the continued availability of capital to finance
our activities. Given these uncertainties, assumptions and risk factors,
readers are cautioned not to place undue reliance on such forward-looking
statements. We disclaim any obligation to update any such factors or to
publicly announce the result of any revisions to any of the forward-looking
statements contained in this report to reflect future results, events or
(1) Description and statistics taken from Canadian Association of Cardiac
Rehabilitation website found at: http://www.cacr.ca; Paus Jenssen,
L. Erik, Atrial Fibrillation Following Coronary Artery Bypass Grafting.
Canadian Association of Cardiac Rehabilitation (CACR) newsletter:
(2) Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE,
Henderson WG, et al. Atrial fibrillation after cardiac surgery: a major
morbid event? Ann Surg 1997;226:501-11.
(3) Aranski SF, ShawDP, Adams DH, Rizzo RJ, Couper GS, VanderVliet
M. Predictors of atrial fibrillation after coronary artery surgery.
Current trends and impact on hospital resources.
CONTACT: Angiotech Contacts: Jodi Regts, Angiotech Pharmaceuticals,
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction2
. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC3
. Angiotech to participate in RBC 2007 Healthcare Conference4
. Angiotech to participate in Bank of America 2007 Credit Conference5
. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook6
. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line7
. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial8
. Angiotech to participate in UBS Global Life Sciences Conference9
. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation10
. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office11
. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line